SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity

@article{Panasci1996SarCNUA,
  title={SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity},
  author={Lawrence Panasci and Daniela Di Marcantonio and Adrian J. No{\"e}},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1996},
  volume={37},
  pages={505-508}
}
High-grade gliomas are inevitably fatal, with an average survival of 6–12 months following surgery [16]. One of the most effective chemotherapeutic agents for malignant gliomas is bis-chloroethylnitrosourea (BCNU) [17]. The chloroethylnitrosoureas result in dose limiting toxicity of delayed cumulative myelosuppression [2]. In spite of its demonstrated… CONTINUE READING